Boston begins German trials on paclitaxel-coated stents
This article was originally published in Clinica
Clinical trials of Boston Scientific's paclitaxel-coated coronary stents are to begin in Germany. The dose-escalating study, which aims to evaluate the safety and feasibility of the device for reducing restenosis, is the first human trial of the company's drug-coated stents for coronary indications. The trial is due to begin in the second quarter of this year.
You may also be interested in...
The C-suite leaders schemed to falsely record shipments of unwanted products to distributors as sales so the company could meet revenue projections, the government charged.
Gallium has been approved as a diagnostic agent by the US agency to help early detection of prostate cancer spread in patients who qualify for treatment with surgery or radiation therapy.
A joint report by the US Government Accountability Office and the National Academy of Sciences slams the FDA for dawdling on final software as a medical device rules.